
U.S. stocks ended a turbulent week in the red as a sharp technology sell-off, the midterm election results, and growing concerns over AI spending rattled Wall Street. The S&P 500
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| RMD | Resmed | 245.52 | -5.88 | -2.34% |
| Name | Price | % Change | |
|---|---|---|---|
| $245.52 | -2.34% |

U.S. stocks ended a turbulent week in the red as a sharp technology sell-off, the midterm election results, and growing concerns over AI spending rattled Wall Street. The S&P 500

Canaccord downgraded ResMed (RMD) to Hold from Buy with a price target of A$35.61, down from A$40. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial

Resmed Inc (($RMD)) has held its Q1 earnings call. Read on for the main highlights of the call. ResMed’s fiscal 2027 first-quarter call carried a strongly positive tone, with 7%

RBC Capital raised the firm’s price target on ResMed (RMD) to $288 from $262 and keeps an Outperform rating on the shares. The company delivered a strong Q1, which beat

KeyBanc raised the firm’s price target on ResMed (RMD) to $277 from $267 on higher estimates, while keeping an Overweight rating on the shares. The firm viewed ResMed’s Q1 release

Mizuho analyst Anthony Petrone raised the firm’s price target on ResMed (RMD) to $270 from $240 and keeps an Outperform rating on the shares. Published first on TheFly – the

Wells Fargo raised the firm’s price target on ResMed (RMD) to $250 from $215 and keeps an Equal Weight rating on the shares. The firm notes Q1 sales and EPS

Baird raised the firm’s price target on ResMed (RMD) to $246 from $238 and keeps a Neutral rating on the shares. The firm updated its model following positive Q1 results

Citi raised the firm’s price target on ResMed (RMD) to $270 from $240 and keeps a Neutral rating on the shares. The company reported a 9% core earnings beat in

An announcement from Resmed ( ($RMD) ) is now available. Resmed reported first-quarter fiscal 2027 results on October 29, 2026, posting a 6% rise in revenue to $1.415 billion and
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| hold | Reiterated | Nov 2, 2026 | ||||
| buy | Reiterated | Nov 2, 2026 | ||||
| hold | Reiterated | Oct 30, 2026 | ||||
| buy | Reiterated | Oct 30, 2026 | ||||
| hold | Reiterated | Oct 30, 2026 | ||||
| hold | Reiterated | Oct 30, 2026 | ||||
| hold | Reiterated | Oct 30, 2026 | ||||
| buy | Reiterated | Oct 30, 2026 | ||||
| buy | Reiterated | Oct 30, 2026 | ||||
| hold | Assigned | Oct 30, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Jan 28, 2027TBA | $33.46B | $2.99 | $1.46B | 1.93 | 21.69 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.